SEC Form 4 · accession 0000899243-18-018316
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Gardner
Officer — See Remarks · Director
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 25, 2018 | C | 25,719 | — | A | 292,990 | I | By J.P. Gardner Irrevocable Trust |
| Common StockF1 | Jun 25, 2018 | C | 21,677 | — | A | 359,092 | I | By P.S. Gardner Irrevocable Trust |
| Common StockF2 | Jun 25, 2018 | P | 400 | $15.00 | A | 363,212 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | — | Jun 25, 2018 | C | 30,000 | D | — | — | Common Stock | 11,611 | 0 | I |
| Series A Preferred StockF1 | — | Jun 25, 2018 | C | 36,700 | D | — | — | Common Stock | 14,203 | 0 | I |
| Series B Preferred StockF1 | — | Jun 25, 2018 | C | 15,000 | D | — | — | Common Stock | 5,804 | 0 | I |
| Series B Preferred StockF1 | — | Jun 25, 2018 | C | 19,314 | D | — | — | Common Stock | 7,474 | 0 | I |
| Series C Preferred StockF1 | — | Jun 25, 2018 | C | 21,459 | D | — | — | Common Stock | 8,304 | 0 | I |
Explanation of responses
- F1The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.
- F2Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.
Remarks
President & Chief Executive Officer